Dashboard
1
The company has declared negative results for the last 2 consecutive quarters
- The company has declared negative results in Dec 24 after 5 consecutive negative quarters
- NET SALES(HY) At CNY 145.6 MM has Grown at -27.32%
- NET PROFIT(HY) At CNY 20.05 MM has Grown at -46.72%
- OPERATING CASH FLOW(Y) Lowest at CNY 106.63 MM
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,632 Million (Small Cap)
20.00
NA
0.00%
-0.90
3.90%
0.78
Revenue and Profits:
Net Sales:
109 Million
(Quarterly Results - Mar 2026)
Net Profit:
41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.9%
0%
56.9%
6 Months
67.69%
0%
67.69%
1 Year
66.31%
0%
66.31%
2 Years
40.87%
0%
40.87%
3 Years
127.12%
0%
127.12%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Innovita Biological Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.76%
EBIT Growth (5y)
78.79%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
0.26
Tax Ratio
8.78%
Dividend Payout Ratio
42.01%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
128.44%
ROE (avg)
9.63%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
0.78
EV to EBIT
-3.96
EV to EBITDA
-3.10
EV to Capital Employed
-1.24
EV to Sales
-0.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
3.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
108.80
207.00
-47.44%
Operating Profit (PBDIT) excl Other Income
39.40
109.90
-64.15%
Interest
0.10
0.00
Exceptional Items
4.30
3.70
16.22%
Consolidate Net Profit
40.60
95.30
-57.40%
Operating Profit Margin (Excl OI)
362.30%
488.50%
-12.62%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -47.44% vs -26.49% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -57.40% vs -34.77% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
418.30
617.90
-32.30%
Operating Profit (PBDIT) excl Other Income
165.00
264.20
-37.55%
Interest
0.30
0.20
50.00%
Exceptional Items
5.80
7.10
-18.31%
Consolidate Net Profit
144.50
246.90
-41.47%
Operating Profit Margin (Excl OI)
308.30%
379.50%
-7.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -32.30% vs 29.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -41.47% vs 41.98% in Dec 2024
About Innovita Biological Technology Co., Ltd. 
Innovita Biological Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






